Business
Alembic Pharma Q2 net surges 81% to ₹335 crore
“U.S. business was driven by strong volume growth and new launches. In U.S. Branded, we are encouraged by the traction building across our existing portfolio,” said

“U.S. business was driven by strong volume growth and new launches. In U.S. Branded, we are encouraged by the traction building across our existing portfolio,” said
🔥 Get India’s hottest story up to 4× a day, plus a daily alert on your rights.
📡 Verified Wire Agency
Original Resource
Comments 0